Medication combo to prevent lymphoma relapse after transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 55 years old.
- You have had a stem cell transplant for T-cell lymphoma or leukemia.
- You have at least one high-risk factor for relapse (such as high white blood cell count at diagnosis, a large tumor in the chest, or certain gene changes).
- You are currently in remission or have stable blood counts (ANC >= 1.0 and platelets >= 50).
- You do not have active graft-versus-host disease (GVHD) or severe organ problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a drug called azacitidine along with donor lymphocyte infusions (white blood cells from your original donor) can help prevent leukemia from coming back after a stem cell transplant. If you are at high risk for relapse, this combination might lower that risk.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
This trial tests a combination of two drugs (cidabenamine and azacitidine) to help prevent peripheral T-cell lymphoma from coming back after a donor stem cell transplant. It is for patients who are at high risk of progression and have already had a transplant.
This trial studies a combination of two medicines (venetoclax and azacitidine) as a bridge to a stem cell transplant for people with a hard-to-treat type of AML (like secondary AML or with low bone marrow cells). The goal is to get the leukemia under control so a transplant can be done successfully.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.